Fondazione IRCCS: Istituto Nazionale dei Tumori

The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients (2020) Alman B, Attia S, Baumgarten C, Benson C, Blay JY, Bonvalot S, Breuing J, et al. Journal article, Review article Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer (2020) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees (2020) Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, et al. Journal article A network analysis to identify mediators of germline-driven differences in breast cancer prognosis (2020) Escala-Garcia M, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Ashworth A, Auer PL, et al. Journal article Genetic and phenotypic spectrum associated with IFIH1 gain-of-function (2020) Rice G, Park S, Gavazzi F, Adang LA, Ayuk LA, Van Eyck L, Seabra L, et al. Journal article Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy (2020) Daillere R, Derosa L, Bonvalet M, Segata N, Routy B, Gariboldi M, Budinska E, et al. Journal article, Review article Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer (2020) Roberti MP, Yonekura S, Duong CP, Picard M, Ferrere G, Tidjani Alou M, Rauber C, et al. Journal article Prediction and clinical utility of a contralateral breast cancer risk model (2019) Giardiello D, Steyerberg EW, Hauptmann M, Adank MA, Akdeniz D, Blomqvist C, Bojesen SE, et al. Journal article Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution Adverse events 2.0-Let us get SERIOs New reporting for adverse event outcomes needed in the era of immunooncology (2019) Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, et al. Journal article, Letter